DiaMedica Therapeutics Inc. (DMAC) 已获得加拿大卫生部的许可,将启动其候选药物Dm199用于治疗先兆子痫的二期临床试验。此项批准标志着该药物在开发进程中迈出了关键一步,为后续研究铺平了道路。
DiaMedica Therapeutics Inc. (DMAC) 已获得加拿大卫生部的许可,将启动其候选药物Dm199用于治疗先兆子痫的二期临床试验。此项批准标志着该药物在开发进程中迈出了关键一步,为后续研究铺平了道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.